UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Applied Therapeutics, Inc. (NASDAQ:APLT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 119,035 shares of the company’s stock, valued at approximately $102,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.10% of Applied Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of APLT. Vestal Point Capital LP increased its position in Applied Therapeutics by 904.4% during the 4th quarter. Vestal Point Capital LP now owns 11,500,000 shares of the company’s stock valued at $9,846,000 after buying an additional 10,355,000 shares in the last quarter. VR Adviser LLC boosted its holdings in Applied Therapeutics by 1.7% in the fourth quarter. VR Adviser LLC now owns 9,990,591 shares of the company’s stock worth $8,554,000 after acquiring an additional 165,591 shares in the last quarter. Propel Bio Management LLC grew its stake in shares of Applied Therapeutics by 46.4% in the fourth quarter. Propel Bio Management LLC now owns 9,615,420 shares of the company’s stock worth $8,233,000 after acquiring an additional 3,047,562 shares during the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in shares of Applied Therapeutics by 2,458.3% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 8,762,291 shares of the company’s stock valued at $7,502,000 after acquiring an additional 8,419,781 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its position in shares of Applied Therapeutics by 2,511.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,420,920 shares of the company’s stock worth $4,642,000 after purchasing an additional 5,213,370 shares during the last quarter. Institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Price Performance

Shares of NASDAQ:APLT opened at $0.37 on Friday. Applied Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $10.62. The company has a market cap of $51.68 million, a P/E ratio of -0.23 and a beta of 1.86. The stock’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.78.

Applied Therapeutics (NASDAQ:APLT) last issued its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). The business had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.61 million. On average, sell-side analysts anticipate that Applied Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Analysts Set New Price Targets

APLT has been the topic of a number of analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $1.50 price target on shares of Applied Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen raised shares of Applied Therapeutics to a “sell” rating in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Applied Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.